Furthering Asbestos Claims Transparency Act of 2015
.svg)
Furthering Asbestos Claims Transparency Act of 2015
The Furthering Asbestos Claims Transparency Act of 2015, also known as the FACT Act, was a proposed piece of legislation in the United States Congress. The primary aim of the Act was to increase transparency in the process of filing asbestos-related claims.
Background[edit | edit source]
Asbestos exposure has been linked to various health issues, including mesothelioma and lung cancer. Due to the long latency period of these diseases, individuals exposed to asbestos may not develop symptoms until many years later. As a result, asbestos litigation has been a significant issue in the United States legal system.
Provisions[edit | edit source]
The FACT Act sought to address concerns about potential fraud and abuse in asbestos litigation by requiring the public disclosure of information related to asbestos claims. Specifically, the Act would have mandated the reporting of detailed information about asbestos trust claims, including the names of claimants and the basis for their claims.
Controversy[edit | edit source]
Supporters of the FACT Act argued that increased transparency would help prevent fraudulent claims and ensure that compensation reached legitimate victims of asbestos exposure. However, opponents of the Act, including consumer advocacy groups and some legal experts, raised concerns about privacy issues and the potential for the disclosure of sensitive personal information.
Legislative History[edit | edit source]
The Furthering Asbestos Claims Transparency Act of 2015 was introduced in the House of Representatives on January 6, 2015, by Representative Blake Farenthold. The bill passed the House on January 8, 2016, but ultimately did not become law.
Impact[edit | edit source]
While the FACT Act did not pass, the debate surrounding asbestos claims transparency continues to be a topic of discussion in legal and policy circles. Advocates for transparency in asbestos litigation continue to push for reforms to ensure that compensation is distributed fairly and efficiently.
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
